摘要
目的比较荆花胃康胶丸与常规四联用药(质子泵抑制剂+枸橼酸铋+两种抗生素)补救治疗常规根除幽门螺杆菌失败病例的疗效和安全性。方法选择86例经严格规范按根除幽门螺杆菌三联方案(铋剂或雷贝拉唑肠溶胶囊加阿莫西林、甲硝唑或克拉霉素等两种抗生素)治疗失败,随机分成治疗组和对照组。治疗组:荆花胃康胶丸2粒(160mg),每天3次口服,疗程4周,加用雷贝拉唑肠溶胶囊20mg,1天2次口服,疗程1周。对照组:雷贝拉唑肠溶胶囊20mg,1天2次口服,疗程4周,胶铋胶囊200mg+甲硝唑0.5g+克拉霉素0.5g,1天2次,口服,疗程1周。补救治疗后4周进行胃镜检查,C14-尿素呼气试验检查Hp。观察两组治疗前后症状变化。结果幽门螺杆菌根除率:治疗组为62.79%(27/43),对照组为67.44%(29/43),两组比较无明显差异(P>0.05),治疗组未见明显副反应,费用比对照组低。治疗组对胃痛、嗳气、反酸及上腹胀症状改善有显著疗效(均P<0.05)。结论治疗组方案可作为治疗Hp的补充方案,特别是对于不适宜使用抗生素抗Hp治疗的患者提供一种较好的治疗方法。该方案值得在临床推广。
OBJECTIVE To compare the effect and safety of JinghuaWeikang Capsule（JWC） and convention Staphylococcus tetragenus（PPI,bismuth citrate,two antibiotics）in redeem treating the failure of eradication helicobacter pylori（Hp）.METHODS Eighty six patients with failure of eradication Hp which were eradicated by strict standard trilogy（bismuth citrate or Rabeprazole caps,amoxicillin,arilin or Clarithromycin） were randomly divided into the treated group treated with JWC,160mg 3 times per day for 4 weeks and Rabeprazole caps 20mg 2 times per day for one week,the control group treated with Rabeprazole caps 20mg 2 times per day for 4 weeks,Clarithromycin 500mg,mettronidazole 500mg and colloidal bismuth 200mg twice per day for one week,both by orally taking before meal.The Hp status was determined by Starry silver stain or C14-breath test before and four weeks after completion of therapy.Changes of symptom score before and after the reatment were observed.RESULTS Hp eradication rate of in the reated group （62.79%）was similar to those in the control group（67.44%）.That was not significant deviation（both P0.05）.The effect of relieving symptoms including abdominal pain,belching,sour regurgitation and abdominal distension was significantly lower than those in the control group（P0.05）,and the incidence rate of adverse reaction in the reated group was remarkably lower than that in the control group（P0.05）.The reated group was cheaper than the control group.CONCLUSION The reated group is an alternative to triple therapy of Hp,espercially for those who can not benefit form triple therapy or accept antibiotics.so it is worthy of expanding clinically.
出处
《海峡药学》
2011年第5期94-96,共3页
Strait Pharmaceutical Journal
关键词
荆花胃康胶丸
幽门螺杆菌
补救治疗
JinghuaWeikang capsule
helicobacter pylori
redeem treatment
